

Radiopharm receives \$4.85M R&D tax incentive

Sydney, Australia – 21 November 2023 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received a research and development (R&D) tax refund of A\$4,851,839 under the Australian Government's R&D tax incentive.

The refund is in recognition of Radiopharm's R&D activities during the 2023 financial year and will provide important funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications.

The Australian Government R&D tax incentive program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>